Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10381810 | 1.00 | TSHR (0.44) | TSHRTDP1L3MBTL1PKMALDH1A1 | |
| SCHEMBL2299148 | 0.86 | PKM (0.50) | TSHRTDP1L3MBTL1PKMALDH1A1 | |
| SCHEMBL5275541 | 0.86 | TSHR (0.44) | TSHRTDP1L3MBTL1PKMALDH1A1 | |
| SCHEMBL561310 | 0.86 | PKM (0.50) | TSHRTDP1L3MBTL1PKMALDH1A1 | |
| SCHEMBL4536570 | 0.86 | TSHR (0.44) | TSHRTDP1L3MBTL1PKMALDH1A1 | |
| SCHEMBL4663909 | 0.86 | TDP1 (0.46) | TSHRTDP1L3MBTL1PKMALDH1A1 | |
| SCHEMBL2424155 | 0.83 | TDP1 (0.44) | TSHRTDP1L3MBTL1PKMALDH1A1 | |
| SCHEMBL5320639 | 0.81 | KDM4E (0.47) | TSHRTDP1L3MBTL1PKMALDH1A1 | |
| SCHEMBL23043801 | 0.81 | PKM (0.56) | TSHRTDP1L3MBTL1PKMALDH1A1 | |
| SCHEMBL18602612 | 0.79 | PKM (0.50) | TSHRTDP1L3MBTL1PKMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3327013-B1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORP (US) | 2019-04-24 | — | — | EP | disclosed |
| EP-3327013-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | Celgene Corporation (US) | 2018-05-30 | — | — | EP | disclosed |
| EP-3061758-B1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORP (US) | 2018-01-31 | — | — | EP | disclosed |
| US-9801868-B2 | 5-substituted isoindoline compounds | CELGENE CORPORATION (US) | 2017-10-31 | — | — | US | disclosed |
| US-20160346264-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORPORATION | 2016-12-01 | — | — | US | disclosed |
| US-9447070-B2 | 5-substituted isoindoline compounds | CELGENE CORPORATION (US) | 2016-09-20 | — | — | US | disclosed |
| EP-3061758-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | Celgene Corporation (US) | 2016-08-31 | — | — | EP | disclosed |
| EP-2749559-B1 | 5-substituted isoindoline compounds | CELGENE CORP (US) | 2016-04-27 | — | — | EP | disclosed |
| EP-2291365-B1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORP (US) | 2015-03-11 | — | — | EP | disclosed |
| US-20150005303-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORPORATION | 2015-01-01 | — | — | US | disclosed |
| CN-102112463-A | 5-substituted isoindoline compounds | CELGENE CORP | 2011-06-29 | — | — | CN | disclosed |
| EP-2291365-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORPORATION (US) | 2011-03-09 | — | — | EP | disclosed |
| WO-2009145899-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORPORATION (US) | 2009-12-03 | — | — | WO | disclosed |
| US-20090142297-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORPORATION | 2009-06-04 | — | — | US | disclosed |
| EP-2057143-A2 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORPORATION (US) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008027542-A2 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORPORATION (US) | 2008-03-06 | — | — | WO | disclosed |
| EP-0203957-B1 | 5-(3,5-DISUBSTITUTED PHENYLAZO)-2-HYDROXYBENZENE ACETIC ACIDS AND SALTS AND LACTONES THEREOF, AND PHARMACEUTICAL COMPOSITIONS OF SAID ACIDS, SALTS, AND LACTONES | PHARMACIA AB (SE) | 1990-03-14 | — | — | EP | disclosed |
| US-4725676-A | 5-(3,5-disubstituted phenylazo)-2-hydroxybenzene-acetic acids and salts and lactones thereof having a potentially inhibitory effect on 15-hydroxy-prostaglandin dehydrogenase | PHARMACIA AB (SE) | 1988-02-16 | — | — | US | disclosed |
| EP-0203957-A1 | 5-(3,5-disubstituted phenylazo)-2-hydroxybenzene acetic acids and salts and lactones thereof, and pharmaceutical compositions of said acids, salts, and lactones. | PHARMACIA AB (SE) | 1986-12-10 | — | — | EP | disclosed |
| WO-1986003195-A1 | NOVEL AZO COMPOUNDS | PHARMACIA AB (SE) | 1986-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160346264-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CYP3A5, CYP3A7, CYP3A4 | TSHR 4360/4885TDP1 1031/4885L3MBTL1 3940/4885 |
| US-20150005303-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CYP3A5, CYP3A7, CYP3A4 | TSHR 4360/4885TDP1 1031/4885L3MBTL1 3940/4885 |
| US-20090142297-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CYP3A5, CYP3A7, CYP3A4 | TSHR 4360/4885TDP1 1031/4885L3MBTL1 3940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.